title: [Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo].
authors.affiliation: Göteborgs universitet.
authors.forename: Helen
authors.initials: H
authors.lastname: Tedeholm
authors.forename: Bengt
authors.initials: B
authors.lastname: Skoog
authors.forename: Jan
authors.initials: J
authors.lastname: Hillert
authors.forename: Björn
authors.initials: B
authors.lastname: Runmarker
authors.forename: Leszek
authors.initials: L
authors.lastname: Stawiarz
authors.forename: Andersen
authors.initials: A
authors.lastname: Oluf
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D015331:Cohort Studies; D004185:Disability Evaluation; D018450:Disease Progression; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D010455:Peptides / Q000627:therapeutic use*; D010919:Placebos; D011379:Prognosis; D012042:Registries; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D010455:Peptides; D010919:Placebos; D000068717:Glatiramer Acetate; D016899:Interferon-beta